Evidence map›Paper›PMID 35042897›Full record

ArticleNature communications2022

53BP1 regulates heterochromatin through liquid phase separation.

Lei Zhang, Xinran Geng, Fangfang Wang, Jinshan Tang, Yu Ichida, Arishya Sharma, Sora Jin, Mingyue Chen, Mingliang Tang, Franklin Mayca Pozo and 9 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 103 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Lei Zhang *Department of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA. zhanglei0222@163.com.ORCID http://orcid.org/0000-0003-1451-0602
Xinran Geng *Department of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.ORCID http://orcid.org/0000-0003-2335-2642
Fangfang Wang *Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Jinshan TangInstitute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Yu IchidaDepartment of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.
Arishya SharmaDepartment of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.
Sora JinDepartment of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.
Mingyue ChenNational 111 Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering, Hubei University of Technology, Wuhan, Hubei, 430068, China.
Mingliang TangCollege of Life Sciences, Wuhan University, Wuhan, Hubei, 430068, China.
Franklin Mayca PozoDepartment of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.ORCID http://orcid.org/0000-0003-0926-3336
Wenxiu WangNational 111 Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering, Hubei University of Technology, Wuhan, Hubei, 430068, China.
Janet WangDepartment of Genetics and Genome Sciences, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.
Michal WozniakDepartment of Pharmacology and Toxicology, Wright State University, Dayton, OH, 45435, USA.ORCID http://orcid.org/0000-0003-2251-8647
Xiaoxia GuoNational 111 Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering, Hubei University of Technology, Wuhan, Hubei, 430068, China.
Masaru MiyagiDepartment of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.
Fulai JinDepartment of Genetics and Genome Sciences, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.ORCID http://orcid.org/0000-0003-0025-4337
Yongjie XuDepartment of Pharmacology and Toxicology, Wright State University, Dayton, OH, 45435, USA.
Xinsheng YaoInstitute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Youwei ZhangDepartment of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA. yxz169@case.edu.ORCID http://orcid.org/0000-0003-0011-7922
Case Western Reserve University · USHubei University of Technology · CNJinan University · CNUniversity School · USWright State University · USWuhan University · CN

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Robust mapping of chromatin loops from sparse or single cell Hi-C data with DeepLoopR01HG009658 · NHGRI · CASE WESTERN RESERVE UNIVERSITY · PI Fulai Jin · 2017 to 2026
$5.1M
Elucidating human beta cell transcriptional regulome with low-input genomic technologiesR01DK113185 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Yan Li · 2018 to 2026
$4.0M
STAG2 mutations and 3D genome organization in glioblastoma multiformeR01CA267872 · NCI · GEORGETOWN UNIVERSITY · PI Fulai Jin, TODD A WALDMAN · 2022 to 2026
$2.7M
Targeting DNA repair in KRAS mutated lung cancer by chemical screeningR01CA230453 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI ZHANG, YOU-WEI · 2019 to 2023
$2.4M
Understanding the variation of induced β-cell differentiation.R01DK131437 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI JIN, FULAI, LI, YAN · 2022 to 2025
$2.4M
DNA Replication Checkpoint in Fission YeastR35GM144307 · NIGMS · WRIGHT STATE UNIVERSITY · PI Yongjie Xu · 2022 to 2026
$1.9M
Signaling Mechanism of the DNA Replication CheckpointR01GM110132 · NIGMS · WRIGHT STATE UNIVERSITY · PI XU, YONGJIE · 2015 to 2020
$1.3M
Leica SP8 Confocal with Hyvolution2 DeconvolutionS10OD024996 · OD · CASE WESTERN RESERVE UNIVERSITY · PI IMANISHI, YOSHIKAZU · 2018 to 2018
$594k
NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA230453NCI NIH HHS R01 CA267872NHGRI NIH HHS R01 HG009658NIDDK NIH HHS R01 DK131437NIGMS NIH HHS R01 GM110132NIGMS NIH HHS R35 GM144307NIH HHS S10 OD024996
6 · The paper itself

Abstract

Human 53BP1 is primarily known as a key player in regulating DNA double strand break (DSB) repair choice; however, its involvement in other biological process is less well understood. Here, we report a previously uncharacterized function of 53BP1 at heterochromatin, where it undergoes liquid-liquid phase separation (LLPS) with the heterochromatin protein HP1α in a mutually dependent manner. Deletion of 53BP1 results in a reduction in heterochromatin centers and the de-repression of heterochromatic tandem repetitive DNA. We identify domains and residues of 53BP1 required for its LLPS, which overlap with, but are distinct from, those involved in DSB repair. Further, 53BP1 mutants deficient in DSB repair, but proficient in LLPS, rescue heterochromatin de-repression and protect cells from stress-induced DNA damage and senescence. Our study suggests that in addition to DSB repair modulation, 53BP1 contributes to the maintenance of heterochromatin integrity and genome stability through LLPS.

Indexed as

AnimalsCell LineCell NucleusChromobox Protein Homolog 5DNA Breaks, Double-StrandedDNA RepairGreen Fluorescent ProteinsHeterochromatinMiceMice, KnockoutMutationProtein DomainsStress, PhysiologicalTumor Suppressor p53-Binding Protein 1Chromobox Protein Homolog 5Green Fluorescent ProteinsHeterochromatinTP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1

Identifiers

PMID35042897
PMCPMC8766474
OpenAlexW4205979806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.